<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03276754</url>
  </required_header>
  <id_info>
    <org_study_id>B1851177</org_study_id>
    <secondary_id>IMPACE</secondary_id>
    <nct_id>NCT03276754</nct_id>
  </id_info>
  <brief_title>Immunization To Prevent Acute COPD Exacerbations</brief_title>
  <official_title>IMMUNIZATION TO PREVENT ACUTE COPD EXACERBATIONS (IMPACE STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicenter observational study, to evaluate the impact of routine clinical&#xD;
      practice vaccination with PCV13 on the reduction of the risk of moderate/severe COPD&#xD;
      exacerbations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic obstructive pulmonary disease (COPD) have been demonstrated to have an&#xD;
      increased risk of pneumococcal disease. Pneumonia is frequent among patients hospitalized for&#xD;
      COPD exacerbations and is associated with increased health care utilization and higher&#xD;
      mortality. Up to 50%-70% of exacerbations can be attributed to respiratory infections by&#xD;
      viruses or bacteria, even more in the most severe patients. They are often associated with&#xD;
      the colonization of airways by multiple bacteria or viruses of low virulence that in normal&#xD;
      conditions are parts of the normal flora of the upper airway. Current recommendations for&#xD;
      immunization of patients with COPD include vaccination against influenza and Streptococcus&#xD;
      pneumoniae. The aim of this study is to evaluate the potential benefits of immunization of&#xD;
      COPD patients with PCV13 and/or against influenza in terms of clinical benefits and quality&#xD;
      of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">January 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Incidence of moderate or severe COPD exacerbations</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of COPD exacerbations reported by participant / follow up time.&#xD;
Moderate COPD exacerbation: those that require antibiotics and/or systemic corticosteroids without hospitalization.&#xD;
Severe COPD exacerbation: those that lead to hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COPD severity</measure>
    <time_frame>2 years</time_frame>
    <description>COPD severity classification (GOLD):&#xD;
GRADE 1: Mild/unknown [FEV1≥ 80%, FEV1/FVC &lt; 0,7 or no spirometry data] GRADE 2: Moderate [50% ≤ FEV1&lt; 80%,FEV1/FVC &lt; 0,7] GRADE 3: Severe [30% ≤ FEV1 &lt; 50%, FEV1/FVC &lt; 0,7] GRADE 4: Very severe [FEV1&lt; 30% o FEV1&lt; 50% plus respiratory failure,FEV1/FVC &lt; 0,7])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Saint George Respiratory Questionnaire Score</measure>
    <time_frame>2 years</time_frame>
    <description>The SGRQ is a specific questionnaire developed to measure health status (quality of life) in patients with chronic airflow limitation.&#xD;
Scores are calculated for three domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CAT (COPD Assessment Tool) questionnaire score</measure>
    <time_frame>2 years</time_frame>
    <description>COPD Assessment Tool is a simple questionnaire that may be used to determine the severity of symptoms. Scores on CAT range from 0-40 with the higher the score, the more severe the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 from baseline</measure>
    <time_frame>2 years</time_frame>
    <description>FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Trough FEV1 was obtained from spirometry, performed as routine clinical practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants vaccinated with PCV13</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants vaccinated with PCV13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of COPD exacerbations/patient/year</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of exacerbations reported by participant / follow up time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean cost per participant</measure>
    <time_frame>2 years</time_frame>
    <description>Overall cost of hospitalization and/or treatment of exacerbation episode based on days of hospitalization /ICU and treatment received.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1540</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>COPD</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects ≥18 years diagnosed with COPD, followed up at the Pulmonology Department of the&#xD;
        partipant centres&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patient ≥18 years diagnosed with COPD (any stage, the subgroups for the analysis would&#xD;
             be based on COPD severity grade)&#xD;
&#xD;
          2. Ability to understand and complete the required QoL questionnaires&#xD;
&#xD;
          3. At least 2 years of clinical history available that includes records of previous&#xD;
             moderate/severe exacerbations, influenza and pneumococcal vaccination history&#xD;
             comorbidities and previous treatments.&#xD;
&#xD;
          4. Spirometry data (maximum 6 months old, or if not available at enrollment, to be&#xD;
             performed as per normal clinical practice at visit 1 +/- one month)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Impossibility to perform prospective follow up&#xD;
&#xD;
          2. Present any immunocompromising condition&#xD;
&#xD;
          3. Present any other respiratory diseases as co-morbidity (subjects with overlap&#xD;
             syndromes COPD-asthma will be excluded. Mixed phenotype defined as: symptoms of&#xD;
             increased variability of airflow and incompletely reversible airflow obstruction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Mutua Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital el Bierzo</name>
      <address>
        <city>Ponferrada</city>
        <state>León</state>
        <zip>24404</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcon</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1851177</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 6, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal infections</keyword>
  <keyword>COPD exacerbations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

